# Cannabinoid Clinical Trials for Anxiety and Tourette Syndrome > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/effects-cannabinoid-formulations-anxiety-clinical-trials/ > **Published:** 2026-04-14T19:43:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:01:51-04:00 > **Clinical Summary:** Explore effects of cannabinoid formulations on anxiety with clinical trial insights. Understand benefits and limitations for anxiety and Tourette syndrome treatment. --- #### Clinical Takeaway Cannabinoid formulations, particularly CBD-containing products, show measurable reductions in anxiety symptoms across multiple study designs, though effect sizes and optimal dosing vary considerably by condition and formulation. Evidence for Tourette syndrome is more limited but suggests potential benefit for tic severity and associated anxiety. Patients and clinicians should interpret these findings cautiously, as study heterogeneity and methodological variability make definitive dosing or formulation recommendations premature. ### #26 Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis. **Citation:** Raminelli Adrieli Oliveira et al. *Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis.* Cannabis and [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/). 2025. PMID: 40956670. **Study type:** Journal Article, Systematic Review, Meta-Analysis  |  **Topic area:** Anxiety & PTSD  |  **CED Score:** 10 Design: 6 Journal: 1 N: 0 Recency: 2 Pop: 2 Human: 1 Risk: -2 **Quality Gate Alerts:** - Preclinical only **Abstract:** Introduction: Cannabinoid formulations have been increasingly proposed as therapeutic potential options for [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) (ADs). Several countries have expanded regulatory frameworks facilitating access to these compounds due to their alleged [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/), including their application in ADs. Given its [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) significance, we evaluated existing evidence regarding the efficacy of different medical cannabinoids as interventions for ADs and related mental conditions. Methods: A comprehensive search was conducted in PubMed, Embase, PsycInfo, Web of Science, Scielo, and Lilacs databases. We included randomized controlled trials (RTCs) assessing the effects of various cannabinoid formulations on patients with ADs and related conditions. Distinct meta-analyses were performed for cannabinoid subtypes. Analyses were conducted using Jamovi software, relying on standardized mean difference (SMD) calculations of pre/post-intervention score changes for both intervention and control groups. Results: We incorporated 21 placebo-controlled RCTs, examining cannabinoid interventions in social anxiety disorder (SAD = 5), generalized anxiety disorder (GAD = 1), post-traumatic stress disorder (PTSD = 7), obsessive-compulsive disorder (OCD = 1), and Tourette syndrome (TS = 7). Data extraction indicated considerable heterogeneity across outcomes, including clinical symptoms, neuroimaging findings, well-being, psychosocial functioning, safety, and tolerability. In studies utilizing pure or enriched CBD, the meta-analytic measure indicated a nonsignificant difference (SMD = -0.40; 95% CI: -0.84/0.03). However, a subgroup analysis of pure CBD compounds yielded a moderate, statistically significant effect size (SMD: -0.61, 95% CI: -1.15/-0.07). For studies investigating pure or enriched delta-9-tetrahydrocannabinol (Δ9-THC), the meta-analytic measure was -0.65 (95% CI: -1.06/-0.24), suggesting a moderate, significant effect favoring Δ9-THC-dominant compounds. In meta-analyses  |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40956670/)[DOI ↗](https://doi.org/10.1177/25785125251378242) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid Formulations for Anxiety and Tourette Syndrome](https://cedclinic.com/cannabinoid-formulations-anxiety-treatment/) Detailed review of different cannabinoid formulations and their therapeutic potential for anxiety and Tourette syndrome. [Read More](https://cedclinic.com/cannabinoid-formulations-anxiety-treatment/) [Cannabinoid Clinical Trials: Anxiety & Tourette Review](https://cedclinic.com/cannabinoid-clinical-trials-anxiety-review/) Comprehensive analysis of [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) investigating cannabinoids for anxiety and Tourette syndrome. [Explore Trials](https://cedclinic.com/cannabinoid-clinical-trials-anxiety-review/) [Cannabinoids for Anxiety & Tourette's: Evidence from Systematic Reviews and Meta-Analyses](https://cedclinic.com/cannabinoid-formulations-anxiety-disorders-evidence-reviews/) Systematic reviews and meta-analyses summarizing the evidence for cannabinoids in treating anxiety and Tourette's. [Learn More](https://cedclinic.com/cannabinoid-formulations-anxiety-disorders-evidence-reviews/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoid%20Clinical%20Trials%20for%20Anxiety%20and%20Tourette%20Syndrome&url=https%3A%2F%2Fcedclinic.com%2Feffects-cannabinoid-formulations-anxiety-clinical-trials%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Feffects-cannabinoid-formulations-anxiety-clinical-trials%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoid%20Clinical%20Trials%20for%20Anxiety%20and%20Tourette%20Syndrome%20https%3A%2F%2Fcedclinic.com%2Feffects-cannabinoid-formulations-anxiety-clinical-trials%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).